Tsu-Yi Chao
Ministry of Health and Welfare(TW)Taipei Medical University-Shuang Ho Hospital(TW)Taipei Medical University(TW)
Publications by Year
Research Areas
Bone Metabolism and Diseases, Bone health and treatments, Cancer Cells and Metastasis, Cancer Treatment and Pharmacology, MicroRNA in disease regulation
Most-Cited Works
- → Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)(2011)1,595 cited
- → Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial(2012)952 cited
- → A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial(2008)305 cited
- → The Uniform Approach to Breast Fine Needle Aspiration Biopsy(1996)145 cited
- → Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP(2004)128 cited
- → Insulin Resistance Promotes Parkinson’s Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling